Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model


Vertex Pharmaceuticals



) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.9%. By the end of trading, Vertex Pharmaceuticals fell $1.05 (-2.5%) to $41.11 on light volume. Throughout the day, 1.4 million shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 2.3 million shares. The stock ranged in price between $40.69-$42.15 after having opened the day at $42.11 as compared to the previous trading day's close of $42.16. Other companies within the Drugs industry that declined today were:

Supernus Pharmaceuticals



), down 8.9%,




), down 8.7%,

China Botanic Pharmaceutical



), down 8.7%, and




), down 7.9%.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for the treatment of serious diseases worldwide. Vertex Pharmaceuticals has a market cap of $8.98 billion and is part of the health care sector. The company has a P/E ratio of 66.8, above the S&P 500 P/E ratio of 17.7. Shares are up 24.8% year to date as of the close of trading on Tuesday. Currently there are 15 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and three rate it a hold.

TheStreet Ratings rates Vertex Pharmaceuticals as a


. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and feeble growth in the company's earnings per share.

On the positive front,




), up 15.2%,




), up 13.3%,

Infinity Pharmaceuticals



), up 10.4%, and




), up 9.9%, were all gainers within the drugs industry with

Onyx Pharmaceuticals



) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!